» Articles » PMID: 26212263

Targeting the Eph System with Peptides and Peptide Conjugates

Overview
Specialty Pharmacology
Date 2015 Jul 28
PMID 26212263
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Eph receptor tyrosine kinases and ephrin ligands constitute an important cell communication system that controls development, tissue homeostasis and many pathological processes. Various Eph receptors/ephrins are present in essentially all cell types and their expression is often dysregulated by injury and disease. Thus, the 14 Eph receptors are attracting increasing attention as a major class of potential drug targets. In particular, agents that bind to the extracellular ephrin-binding pocket of these receptors show promise for medical applications. This pocket comprises a broad and shallow groove surrounded by several flexible loops, which makes peptides particularly suitable to target it with high affinity and selectivity. Accordingly, a number of peptides that bind to Eph receptors with micromolar affinity have been identified using phage display and other approaches. These peptides are generally antagonists that inhibit ephrin binding and Eph receptor/ ephrin signaling, but some are agonists mimicking ephrin-induced Eph receptor activation. Importantly, some of the peptides are exquisitely selective for single Eph receptors. Most identified peptides are linear, but recently the considerable advantages of cyclic scaffolds have been recognized, particularly in light of potential optimization towards drug leads. To date, peptide improvements have yielded derivatives with low nanomolar Eph receptor binding affinity, high resistance to plasma proteases and/or long in vivo half-life, exemplifying the merits of peptides for Eph receptor targeting. Besides their modulation of Eph receptor/ephrin function, peptides can also serve to deliver conjugated imaging and therapeutic agents or various types of nanoparticles to tumors and other diseased tissues presenting target Eph receptors.

Citing Articles

Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adenocarcinoma.

Yao L, Qin W, Hu L, Shi T, Yu Yang J, Li Q Cancer Commun (Lond). 2024; 45(2):143-166.

PMID: 39648610 PMC: 11833672. DOI: 10.1002/cac2.12637.


Transmembrane helix interactions regulate oligomerization of the receptor tyrosine kinase EphA2.

Wirth D, Ozdemir E, Wimley W, Pasquale E, Hristova K J Biol Chem. 2024; 300(7):107441.

PMID: 38838777 PMC: 11263659. DOI: 10.1016/j.jbc.2024.107441.


Lipidation and PEGylation Strategies to Prolong the Half-Life of a Nanomolar EphA4 Receptor Antagonist.

Gomez-Soler M, Olson E, de la Torre E, Zhao C, Lamberto I, Flood D Eur J Med Chem. 2024; 262.

PMID: 38523699 PMC: 10959496. DOI: 10.1016/j.ejmech.2023.115876.


Eph receptors and ephrins in cancer progression.

Pasquale E Nat Rev Cancer. 2023; 24(1):5-27.

PMID: 37996538 PMC: 11015936. DOI: 10.1038/s41568-023-00634-x.


Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity.

Guidetti L, Zappia A, Scalvini L, Ferrari F, Giorgio C, Castelli R J Chem Inf Model. 2023; 63(21):6900-6911.

PMID: 37910792 PMC: 10647059. DOI: 10.1021/acs.jcim.3c01064.


References
1.
Murai K, Nguyen L, Irie F, Yamaguchi Y, Pasquale E . Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. Nat Neurosci. 2002; 6(2):153-60. DOI: 10.1038/nn994. View

2.
Salvucci O, Tosato G . Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res. 2012; 114:21-57. PMC: 3500853. DOI: 10.1016/B978-0-12-386503-8.00002-8. View

3.
Tonna S, Takyar F, Vrahnas C, Crimeen-Irwin B, Ho P, Poulton I . EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis. FASEB J. 2014; 28(10):4482-96. DOI: 10.1096/fj.14-254300. View

4.
Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W . EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells. Oncogene. 2013; 33(21):2737-47. DOI: 10.1038/onc.2013.238. View

5.
Liu Y, Lan X, Wu T, Lang J, Jin X, Sun X . (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor. Nucl Med Biol. 2014; 41(6):450-6. DOI: 10.1016/j.nucmedbio.2014.03.020. View